# USNA earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/USNA) · [Earnings tab](https://www.lopjlb.com/stock/USNA?tab=earnings)

Updated: 2026-11-03T07:04:13

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly CallCards USANA’s story shifts from a 2024 Q3 sales miss driven by weak China spend to a steady rebound in core nutrition sales, highlighted by 12% year‑over‑year growth in Q1 2025 and 7% sequential growth in Q1 2026. Management pivots in 2025 toward a broader product pipeline, launching over 20 new items, refreshing the brand and integrating the Hyatt acquisition, while rolling out an enhanced compensation plan that shows early traction by Q3 2025. The company expands its omnichannel footprint with Hiya launches in Canada and the UK and a rapid Rise Wellness rollout, notably a 143% surge after a Costco Protein Pop launch. Cost pressures emerge as mix shifts toward lower‑margin Rise products, inventory spikes and a $10 M SG&A saving program, while a technology modernization roadmap remains unsettled. Capital remains strong, with cash above $150 M and zero debt, supporting organic growth and M&A. Macro‑headwinds and guidance uncertainty surface in 2025‑2026, but the firm maintains FY26 sales guidance and continues to invest in technology and manufacturing. Overall, USANA moves from a corrective phase to a growth‑oriented trajectory, tempered by margin and macro risks.

## Latest CallCard · Q2

USANA Q2 2026: Core nutritional stable with China momentum; HYA and Rise Wellness face near-term headwinds (digital marketing costs, packaging issue) prompting lowered full-year outlook and $29M goodwill impairment; balance sheet strong with $169M cash, zero debt.','tone': {'mgmt': 0.3, 'mgmt_ration

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** USANA Q2 2026: Core nutritional stable with China momentum; HYA and Rise Wellness face near-term headwinds (digital marketing costs, packaging issue) prompting lowered full-year outlook and $29M goodwill impairment; balance sheet strong with $169M cash, zero debt.','tone': {'mgmt': 0.3, 'mgmt_ration
- **2026 Q1:** USANA Q1 2026: Core nutrition sales up 7% sequentially driven by China; HYA expands to Canada, UK, Target; Rise Wellness surges 143% sequentially on Costco Protein Pop launch; reaffirms FY26 guidance $925M-$1B; investing in tech modernization.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remar
- **2025 Q4:** USANA Q4 FY2025 results show modest sales decline but a clear pivot to growth via Rise Wellness, Hiya, omnichannel retail and technology, with FY2026 net‑sales guidance of 4% mid‑point and cost‑saving initiatives.
- **2025 Q3:** USANA rolls out enhanced compensation plan, sees early traction post-convention; Hiya and Rise Bar drive diversification; cost reduction underway with $4.7M Q4 charge.','tone':{'mgmt':0.3,'mgmt_rationale':'Management highlights early positive signs from compensation plan rollout, improved engagement
- **2025 Q2:** USANA Q2: sales +11%, EPS +36%, debt-free with $151M cash; rolling out compensation enhancements and new tools for brand partners, Hiya integration progressing, Q3 margin pressure from convention and product launches.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management expressed excitement, optimis
- **2025 Q1:** USANA Q1 net sales up 12% cc
- **2024 Q4:** USANA reports solid Q4 with 7% sequential sales growth, 14% EPS growth; 2025 pivot focuses on product launches (20+), incentive enhancements, brand refresh, and Hyatt integration ($145-160M revenue guidance).
- **2024 Q3:** USANA Q3 sales missed expectations due to China weakness (active customers +7% but spend -4%); guiding higher Q4 promos, launching new products, restructuring product dev for 2025 pipeline; capital allocation prioritizes organic investment and M&A over buybacks.','tone': {'mgmt': 0.2, 'mgmt_rational

## Theme arcs

- **China demand recovery** (improving): From a spend decline in Q3 2024 to sequential sales gains in Q1 2026
- **Product pipeline expansion** (new): 20+ launches announced in 2025 and Rise Wellness rollout in 2025‑2026
- **Compensation and incentive enhancements** (improving): Enhanced plan rolled out in Q3 2025 with early positive signs
- **Acquisition integration** (stable): Hyatt integration completed late 2024; Hiya integration progressing
- **Omnichannel and retail expansion** (improving): Hiya launches in Canada/UK and Rise Wellness retail rollout including Costco and Target
- **Margin pressure from mix and inventory** (deteriorating): Rise Wellness near breakeven, 48% inventory increase, mix shift pressures gross margin
- **Technology modernization roadmap** (new): Roadmap introduced in Q4 2025 but timeline not finalized
- **Capital strength and allocation** (stable): Cash >$150 M, zero debt, focus on organic growth and M&A
- **Macro environment risk** (deteriorating): Potential slowdown noted in 2025‑2026 guidance
- **Guidance uncertainty** (deteriorating): Wide revenue/EPS ranges and inventory buildup raise uncertainty

## Fear persistence

- **Macro slowdown potential** [new]: Cited as risk to top‑line growth in 2025‑2026
- **Guidance range uncertainty** [new]: Wide revenue/EPS guidance reflects uncertainty
- **Inventory buildup** [new]: 48% increase tied to Rise and Hiya could pressure working capital
- **Effective tax rate risk** [new]: Geographic misalignment may keep tax rate high (55‑60%)
- **Margin pressure from mix** [new]: Rise Wellness operating near breakeven could dilute overall margin

## Guidance path

2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:vague → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/USNA`